Cleveland BioLabs, Inc. reported that Chief Development Officer, Jean Viallet, MD will leave the company to assume an oncology global clinical research leadership role at Bristol-Myers Squibb, effective January 3, 2014.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0006 USD | -.--% | -14.29% | -99.98% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.26% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- STAB Stock
- STAB Stock
- News Statera Biopharma, Inc.
- Cleveland BioLabs Announces Departure of Jean Viallet, Effective January 3, 2014